Archer Materials Ltd
(ASX:AXE)Share Price and News
About Archer Materials
Archer Materials (ASX: AXE) is a company commercialising two devices. The first is 12CQ, a carbon-based semiconductor technology which could enable mobile quantum devices. It resolves the impediments that have prevented quantum devices, from reaching the mainstream – which currently include the practicalities of operation and scale.
Second is Biochip, a Lab-on-a-Chip technology being developed to enable rapid, detection of diseases. It would allow droplets of biological specimens to be analysed and processed using graphene sensors, thus generating faster and more reliable results than competing technologies.
Archer Materials is the only ASX-listed company, and one of only a few companies in the world attempting to develop such technologies. It has a well-rounded patent portfolio, a proven record of cost control and crucial partnerships with foundries and research partners. Most crucially, it has a very substantial revenue opportunity ahead of it.
Archer Materials Company History
Founded in 2007, Archer Materials initially began its journey focusing on material science and the development of advanced technologies for the electronics industry. Over the years, the company expanded its research to include the high-tech fields of quantum computing and energy storage solutions.
By 2019, it had pivoted completely to its current product suite. Driving the company's value has been technical achievements recorded with both products. With 12CQ, early milestones included demonstrating quantum information detection on-chip and advancing nanofabrication compatible with industry semiconductor processes. More recent progress has seen Archer achieve key technical steps such as single-electron isolation, enhanced spin control and extended coherence times at room temperature — all critical steps towards building a functional quantum device.
With Biochip, Archer has already produced an alpha prototype capable of clinically accurate blood potassium sensing using very small sample volumes, meeting standards that could make it viable for point-of-care or home diagnostics. Next steps include completing a beta prototype in 2026, which will be key for pursuing commercial partnerships with MedTech firms.
Archer’s technical milestones over the years include working with strategic fabrication partners and research institutes (including IMEC, CSIRO and Emergence Quantum), miniaturising its Biochip design for foundry manufacturing, and progressing both device architecture and CMOS integration for commercial scalability.
Future Outlook of Archer Materials Ltd (ASX:AXE)
Archer's outlook depends on the progress with 12CQ and Biochip. Management and industry watchers are treating 2026 as an inflection year where research activity transitions into more product-ready demonstrations and early commercial engagement — a watershed phase for any early-stage deep tech company.
Specifically, 2026 is expected to see a beta prototype and progress towards clinical trials for Biochop. As for 12CQ, continued progress in 2026 toward a functional quantum bit demonstration and scalable device architecture.
Archer’s prospects are tied to deep tech and quantum computing trends where global R&D spending is forecast to grow, and where breakthroughs that reduce complexity and cost (such as room-temperature qubit operation) are highly prized by industrial, defence and scientific users. Separately, the biosensor and diagnostics market is expanding rapidly due to aging populations and chronic disease prevalence, favouring point-of-care innovations like Archer’s Biochip.
Is Archer Materials a Good Stock to Buy?
Archer Materials is fundamentally a speculative, deep-tech investment rather than a traditional commercial company. It does not yet generate meaningful product revenue from its core technologies — the 12CQ quantum technology and the Biochip medical diagnostics platform — and continues to operate at a loss with ongoing R&D expenditure typical of pre-commercial technology developers.
Its upside lies in successful execution of all that it has promised and eventual commercialisation. But the company is highly speculative and its earnings are only on its potential. Archer Materials may be suitable for investors with a high risk tolerance and a long investment horizon who are comfortable with binary outcomes.
It is not a conventional income or value stock, and it is not currently positioned as a stable, profit-generating business.
Our Stock Analysis
Archer Materials Cracks Quantum Readout Challenge as Stock Surges 12%
Archer Materials Just Solved One of Quantum Computing’s Hardest Problems Archer Materials (ASX: AXE) jumped 12% today after unveiling two…
Archer Materials Jumps 25% After Major Quantum Technology Milestone
Archer Materials (ASX: AXE) jumped 25% today after the company announced a major breakthrough that could bring practical quantum computing…
Why Investors Are Watching Archer Materials After a 35% Surge
What if diagnosing a serious disease was as simple as taking a home pregnancy test? Right now, in Adelaide, a…
ASX Semiconductor Stocks: An Ultimate Guide for Investors (2025 edition)
ASX Semiconductor Stocks are amongst the most complicated and volatile companies on the bourse, but also those with amongst the…
TSMC: The ~TW$30tn company that’s the reason why China has an eager eye on Taiwan
Have you ever heard of TSMC (Taiwan Semiconductor Manufacturing Company)? If you haven’t, there are good reasons why you should…
Mark the Pitt Street Research Semiconductor Conference 2025 in your calendars!
The Pitt Street Research Semiconductor Conference 2025 is coming up! Pitt Street Research in partnership with Bell Potter are thrilled…
Frequently Asked Questions
Archer Materials stands out for its focus on developing advanced semiconductor materials, particularly those for quantum computing and energy storage. Its innovations have the potential to revolutionise multiple high-tech industries.